Praxis Precision Medicines

White arrow on a road pointing to the rising sun
Biotech

Praxis' drug reduces seizures but sees 23% discontinuation rate

Praxis has reported a 56.3% median reduction in seizure frequency, encouraging the biotech to push ahead with plans to start a phase 2/3 study.
Nick Paul Taylor Aug 4, 2025 10:22am
success failure signposts

Praxis moves ahead despite phase 3 tremor trial futility finding

Feb 28, 2025 9:11am
brain amyloid alzheimers strings detailed web complicated thought

Praxis epilepsy drug reduces seizures in phase 2 trial

Sep 3, 2024 10:21am
graphic of the brain and the electrical signals that make it up

Praxis' epilepsy drug hits in phase 2, sparking stock rise

Mar 26, 2024 10:24am
stock market down crash fail shares

Praxis share price halved by tremor fail but still plans phase 3

Mar 3, 2023 9:05am
graphic of the brain and the electrical signals that make it up

Praxis ends year on high with $100M biobucks UCB deal

Dec 14, 2022 5:29am